Pluri Inc

PLUR

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Picking dividend shares in 2026? Here’s where to look

A new report from Morningstar shows opportunities for income investors.
stocks

Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?

With outstanding long-term estimates, here’s what we think of Nvidia stock.
stocks

Wide moat ASX listed global leader keeps winning

Latest earnings show continued strength.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,721.4031.90-0.36%
CAC 407,953.7714.16-0.18%
DAX 4023,204.1423.610.10%
Dow JONES (US)45,927.95163.79-0.36%
FTSE 1009,507.4144.89-0.47%
HKSE25,830.6599.38-0.38%
NASDAQ22,521.9889.140.40%
Nikkei 22548,537.70165.28-0.34%
NZX 50 Index13,326.9015.92-0.12%
S&P 5006,625.147.820.12%
S&P/ASX 2008,447.9035.60-0.42%
SSE Composite Index3,946.746.930.18%

Market Movers